{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:52:31Z","timestamp":1791413551694,"version":"4.3.3"},"reference-count":157,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Parkinson's disease (PD) is a complex neurological condition caused due to inheritance,\nenvironment, and behavior among various other parameters. The onset, diagnosis, course of therapy,\nand future of PD are thoroughly examined in this comprehensive review. This review also presents\ninsights into pathogenic mechanisms of reactive microgliosis, Lewy bodies, and their functions\nin the evolution of PD. It addresses interaction complexity with genetic mutations, especially\nin genes such as UCH-L1, parkin, and \u03b1-synuclein, which illuminates changes in the manner dopaminergic\ncells handle proteins and use proteases. This raises the improved outcomes and life\nquality for those with PD. Potential treatments for severe PD include new surgical methods like\nDeep Brain Stimulation (DBS). Further, exploration of non-motor manifestations, such as cognitive\nimpairment, autonomic dysfunction, and others, is covered in this review article. These symptoms\nhave a significant impact on patients' quality of life. Furthermore, one of the emerging therapeutic\nroutes that are being investigated is neuroprotective medicines that aim to prevent the aggregation\nof \u03b1-synuclein and interventions that modify the progression of diseases. The review concludes\nby stressing the dynamic nature of PD research and the potential game-changing impact of\nprecision medicines on current approaches to therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113894501319817240919103802","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T06:21:05Z","timestamp":1727763665000},"page":"17-32","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Enhancements in Parkinson's Disease Management: Leveraging Levodopa Optimization and Surgical Breakthroughs"],"prefix":"10.2174","volume":"26","author":[{"given":"Ritika","family":"Sharma","sequence":"first","affiliation":[{"name":"University Institute of Pharma Sciences (UIPS), Chandigarh University NH-95, Chandigarh Ludhiana Highway,\nMohali, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avneet","family":"Kour","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab-140401, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3440-1884","authenticated-orcid":true,"given":"Hitesh Kumar","family":"Dewangan","sequence":"additional","affiliation":[{"name":"University Institute of Pharma Sciences (UIPS), Chandigarh University NH-95, Chandigarh Ludhiana Highway,\nMohali, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"105327","DOI":"10.1016\/j.neuint.2022.105327","volume":"156","author":"Yadav D.","year":"2022","unstructured":"Yadav D.; Kumar P.; Restoration and targeting of aberrant neurotransmitters in Parkinson\u2019s disease therapeutics. Neurochem Int  2022,156,105327","journal-title":"Neurochem Int"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/cells10040735","volume":"10","author":"Speranza L.","year":"2021","unstructured":"Speranza L.; di Porzio U.; Viggiano D.; de Donato A.; Volpicelli F.; Dopamine: The neuromodulator of long-term synaptic plasticity, reward and movement control. Cells  2021,10(4),735","journal-title":"Cells"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/brainsci9090239","volume":"9","author":"Palakurthi B.","year":"2019","unstructured":"Palakurthi B.; Burugupally S.P.; Postural instability in parkinson\u2019s disease: A review. Brain Sci  2019,9(9),239","journal-title":"Brain Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","volume":"10","author":"Ramesh S.","year":"2023","unstructured":"Ramesh S.; Arachchige A.S.P.M.; Depletion of dopamine in Parkinson\u2019s disease and relevant therapeutic options: A review of the literature. AIMS Neurosci  2023,10(3),200-231","journal-title":"AIMS Neurosci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/00207454.2018.1486837","volume":"129","author":"Khan A.U.","year":"2019","unstructured":"Khan A.U.; Akram M.; Daniyal M.; Zainab R.; Ashraf G.M.; Perveen A.; Mathew B.; Barreto G.E.; Awareness and current knowledge of Parkinson\u2019s disease: A neurodegenerative disorder. Int J Neurosci  2019,129(1),55-93","journal-title":"Int J Neurosci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/biom11040612","volume":"11","author":"Church F.C.","year":"2021","unstructured":"Church F.C.; Treatment options for motor and non-motor symptoms of parkinson\u2019s disease. Biomolecules  2021,11(4),612","journal-title":"Biomolecules"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"9082","DOI":"10.3390\/ijms22169082","volume":"22","author":"Jagaran K.","year":"2021","unstructured":"Jagaran K.; Singh M.; Nanomedicine for neurodegenerative disorders: Focus on alzheimer\u2019s and parkinson\u2019s diseases. Int J Mol Sci  2021,22(16),9082","journal-title":"Int J Mol Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-981-13-9431-7_17","volume":"1","author":"Zahra W.","year":"2020","unstructured":"Zahra W.; Rai S.N.; Birla H.; Singh S.S.; Dilnashin H.; Rathore A.S.; Singh S.P.; The global economic impact of neurodegenerative diseases: Opportunities and challenges. Bioeconomy Sustainable Dev  2020,1,333-345","journal-title":"Bioeconomy Sustainable Dev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/pharmaceutics15030839","volume":"15","author":"Pe&#xF1;a-D&#xED;az S.","year":"2023","unstructured":"Pe&#xF1;a-D&#xED;az S.; Garc&#xED;a-Pardo J.; Ventura S.; Development of small molecules targeting &#x3B1;-synuclein aggregation: A promising strategy to treat parkinson\u2019s disease. Pharmaceutics  2023,15(3),839","journal-title":"Pharmaceutics"},{"key":"ref=10","first-page":"249","volume":"88","author":"Jagadeesan A.J.","year":"2017","unstructured":"Jagadeesan A.J.; Murugesan R.; Vimala Devi S.; Meera M.; Madhumala G.; Vishwanathan Padmaja M.; Ramesh A.; Banerjee A.; Sushmitha S.; Khokhlov A.N.; Marotta F.; Pathak S.; Current trends in etiology, prognosis and therapeutic aspects of Parkinson\u2019s disease: A review. Acta Biomed  2017,88(3),249-262","journal-title":"Acta Biomed"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/mds.26120","volume":"30","author":"Lees A.J.","year":"2015","unstructured":"Lees A.J.; Tolosa E.; Olanow C.W.; Four pioneers of L-dopa treatment: Arvid carlsson, oleh hornykiewicz, george cotzias, and melvin yahr. Mov Disord  2015,30(1),19-36","journal-title":"Mov Disord"},{"key":"ref=12","first-page":"229","volume":"5","author":"Poewe W.","year":"2010","unstructured":"Poewe W.; Antonini A.; Zijlmans J.C.; Burkhard P.R.; Vingerhoets F.; Levodopa in the treatment of Parkinson\u2019s disease: An old drug still going strong. Clin Interv Aging  2010,5,229-238","journal-title":"Clin Interv Aging"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/00004691-200401000-00003","volume":"21","author":"Volkmann J.","year":"2004","unstructured":"Volkmann J.; Deep brain stimulation for the treatment of Parkinson\u2019s disease. J Clin Neurophysiol  2004,21(1),6-17","journal-title":"J Clin Neurophysiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41531-022-00307-w","volume":"8","author":"Farrow S.L.","year":"2022","unstructured":"Farrow S.L.; Cooper A.A.; O\u2019Sullivan J.M.; Redefining the hypotheses driving Parkinson\u2019s diseases research. NPJ Parkinsons Dis  2022,8(1),45","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fnana.2018.00113","volume":"12","author":"Del Rey N.L.G.","year":"2018","unstructured":"Del Rey N.L.G.; Quiroga-Varela A.; Garbayo E.; Carballo-Carbajal I.; Fern&#xE1;ndez-Santiago R.; Monje M.H.G.; Trigo-Damas I.; Blanco-Prieto M.J.; Blesa J.; Advances in Parkinson\u2019s disease: 200 years later. Front Neuroanat  2018,12,113","journal-title":"Front Neuroanat"},{"key":"ref=16","author":"Kouli A.","year":"2018","unstructured":"Kouli A.; Torsney K.M.; Kuan W-L.;  Parkinson\u2019s disease: Pathogenesis and clinical aspects  2018","journal-title":"Parkinson\u2019s disease: Pathogenesis and clinical aspects"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fneur.2020.00524","volume":"11","author":"Rajan R.","year":"2020","unstructured":"Rajan R.; Divya K.P.; Kandadai R.M.; Yadav R.; Satagopam V.P.; Madhusoodanan U.K.; Agarwal P.; Kumar N.; Ferreira T.; Kumar H.; Sreeram Prasad A.V.; Shetty K.; Mehta S.; Desai S.; Kumar S.; Prashanth L.K.; Bhatt M.; Wadia P.; Ramalingam S.; Wali G.M.; Pandey S.; Bartusch F.; Hannussek M.; Kr&#xFC;ger J.; Kumar-Sreelatha A.; Grover S.; Lichtner P.; Sturm M.; Roeper J.; Busskamp V.; Chandak G.R.; Schwamborn J.; Seth P.; Gasser T.; Riess O.; Goyal V.; Pal P.K.; Borgohain R.; Kr&#xFC;ger R.; Kishore A.; Sharma M.; Genetic architecture of parkinson\u2019s disease in the indian population: Harnessing genetic diversity to address critical gaps in parkinson\u2019s disease research. Front Neurol  2020,11,524","journal-title":"Front Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"S399","DOI":"10.3233\/JAD-220682","volume":"94","author":"Naren P.","year":"2023","unstructured":"Naren P.; Cholkar A.; Kamble S.; Khan S.S.; Srivastava S.; Madan J.; Mehra N.; Tiwari V.; Singh S.B.; Khatri D.K.; Pathological and therapeutic advances in parkinson\u2019s disease: Mitochondria in the interplay. J Alzheimers Dis  2023,94(s1),S399-S428","journal-title":"J Alzheimers Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41531-022-00410-y","volume":"8","author":"Willis A.W.","year":"2022","unstructured":"Willis A.W.; Roberts E.; Beck J.C.; Fiske B.; Ross W.; Savica R.; Van Den Eeden S.K.; Tanner C.M.; Marras C.; Alcalay R.; Schwarzschild M.; Racette B.; Chen H.; Church T.; Wilson B.; Doria J.M.; Incidence of Parkinson disease in North America. NPJ Parkinsons Dis  2022,8(1),170","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"Polymeropoulos M.H.","year":"1997","unstructured":"Polymeropoulos M.H.; Lavedan C.; Leroy E.; Ide S.E.; Dehejia A.; Dutra A.; Pike B.; Root H.; Rubenstein J.; Boyer R.; Stenroos E.S.; Chandrasekharappa S.; Athanassiadou A.; Papapetropoulos T.; Johnson W.G.; Lazzarini A.M.; Duvoisin R.C.; Di Iorio G.; Golbe L.I.; Nussbaum R.L.; Mutation in the &#x3B1;-synuclein gene identified in families with Parkinson\u2019s disease. Science  1997,276(5321),2045-2047","journal-title":"Science"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/brainsci13071005","volume":"13","author":"Ciurea A.V.","year":"2023","unstructured":"Ciurea A.V.; Neac\u0219u C.; Carare R.O.; Ahmed A.I.; Marincu I.; Moraru I.; Unraveling molecular and genetic insights into neurodegenerative diseases: advances in understanding alzheimer\u2019s, Parkinson\u2019s, ALS, and huntington\u2019s disease. Brain Sci  2023,13(5),749","journal-title":"Brain Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"104782","DOI":"10.1016\/j.nbd.2020.104782","volume":"137","author":"Bandres-Ciga S.","year":"2020","unstructured":"Bandres-Ciga S.; Diez-Fairen M.; Kim J.J.; Singleton A.B.; Vitale D.; Blauwendraat C.; Cookson M.R.; Singleton A.; Genetics of Parkinson\u2019s disease: An introspection of its journey towards precision medicine. Neurobiol Dis  2020,137,104782","journal-title":"Neurobiol Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1586\/erm.10.86","volume":"10","author":"Mellick G.D.","year":"2010","unstructured":"Mellick G.D.; Silburn P.A.; Sutherland G.T.; Siebert G.A.; Exploiting the potential of molecular profiling in Parkinson\u2019s disease: Current practice and future probabilities. Expert Rev Mol Diagn  2010,10(8),1035-1050","journal-title":"Expert Rev Mol Diagn"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41531-021-00179-6","volume":"7","author":"Miller K.M.","year":"2021","unstructured":"Miller K.M.; Mercado N.M.; Sortwell C.E.; Synucleinopathy-associated pathogenesis in Parkinson\u2019s disease and the potential for brain-derived neurotrophic factor. NPJ Parkinsons Dis  2021,7(1),35","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1042\/BST0351228","volume":"35","author":"Baron M.","year":"2007","unstructured":"Baron M.; Kudin A.P.; Kunz W.S.; Mitochondrial dysfunction in neurodegenerative disorders. Biochem Soc Trans  2007,35(5),1228-1231","journal-title":"Biochem Soc Trans"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"175133","DOI":"10.1016\/j.ejphar.2022.175133","volume":"930","author":"Thapa K.","year":"2022","unstructured":"Thapa K.; Khan H.; Kanojia N.; Singh T.G.; Kaur A.; Kaur G.; Therapeutic insights on Ferroptosis in Parkinson\u2019s disease. Eur J Pharmacol  2022,930,175133","journal-title":"Eur J Pharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/biology8020038","volume":"8","author":"Chen C.","year":"2019","unstructured":"Chen C.; Turnbull D.M.; Reeve A.K.; Mitochondrial dysfunction in parkinson\u2019s disease\u2014cause or consequence? Biology (Basel)  2019,8(2),38","journal-title":"Biology (Basel)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"567129","DOI":"10.3389\/fnins.2020.567129","volume":"14","author":"Indrieri A.","year":"2020","unstructured":"Indrieri A.; Pizzarelli R.; Franco B.; De Leonibus E.; Cennamo G.; Nicolai R.; D\u2019Amico A.; Vozzi G.; Filosa S.; Carella M.; Salvatore F.; Franco B.; Dopamine, alpha-synuclein, and mitochondrial dysfunctions in parkinsonian eyes. Front Neurosci  2020,14,567129","journal-title":"Front Neurosci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1056\/NEJM200005253422103","volume":"342","author":"L&#xFC;cking C.B.","year":"2000","unstructured":"L&#xFC;cking C.B.; D&#xFC;rr A.; Bonifati V.; Vaughan J.; De Michele G.; Gasser T.; Harhangi B.S.; Meco G.; Den&#xE8;fle P.; Wood N.W.; Agid Y.; Nicholl D.; Breteler M.M.B.; Oostra B.A.; De Mari M.; Marconi R.; Filla A.; Bonnet A-M.; Broussolle E.; Pollak P.; Rascol O.; Rosier M.; Arnould A.; Brice A.; Association between early-onset Parkinson\u2019s disease and mutations in the parkin gene. N Engl J Med  2000,342(21),1560-1567","journal-title":"N Engl J Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12017-017-8454-x","volume":"19","author":"Lopes F.M.","year":"2017","unstructured":"Lopes F.M.; Bristot I.J.; da Motta L.L.; Parsons R.B.; Klamt F.; Mimicking Parkinson\u2019s disease in a dish: Merits and pitfalls of the most commonly used dopaminergic in vitro models. Neuromolecular Med  2017,19(2-3),241-255","journal-title":"Neuromolecular Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.3390\/ijms20215312","volume":"20","author":"Lin K.J.","year":"2019","unstructured":"Lin K.J.; Lin K.L.; Chen S.D.; Liou C.W.; Chuang Y.C.; Lin H.Y.; Lin T.K.; The overcrowded crossroads: Mitochondria, alpha-synuclein, and the endo-lysosomal system interaction in Parkinson\u2019s disease. Int J Mol Sci  2019,20(21),5312","journal-title":"Int J Mol Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10571-020-00914-2","volume":"41","author":"Wang X.L.","year":"2021","unstructured":"Wang X.L.; Feng S.T.; Wang Z.Z.; Yuan Y.H.; Chen N.H.; Zhang Y.; Parkin, an E3 ubiquitin ligase, plays an essential role in mitochondrial quality control in Parkinson\u2019s disease. Cell Mol Neurobiol  2021,41(7),1395-1411","journal-title":"Cell Mol Neurobiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"e4756","DOI":"10.1371\/journal.pone.0004756","volume":"4","author":"Gegg M.E.","year":"2009","unstructured":"Gegg M.E.; Cooper J.M.; Schapira A.H.V.; Taanman J.W.; Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS One  2009,4(3),e4756","journal-title":"PLoS One"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.tins.2014.03.004","volume":"37","author":"Scarffe L.A.","year":"2014","unstructured":"Scarffe L.A.; Stevens D.A.; Dawson V.L.; Dawson T.M.; Parkin and PINK1: Much more than mitophagy. Trends Neurosci  2014,37(6),315-324","journal-title":"Trends Neurosci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00401-011-0902-3","volume":"123","author":"Pilsl A.","year":"2012","unstructured":"Pilsl A.; Winklhofer K.F.; Parkin, PINK1 and mitochondrial integrity: Emerging concepts of mitochondrial dysfunction in Parkinson\u2019s disease. Acta Neuropathol  2012,123(2),173-188","journal-title":"Acta Neuropathol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"102327","DOI":"10.1016\/j.arr.2024.102327","volume":"98","author":"Thapa R.","year":"2024","unstructured":"Thapa R.; Moglad E.; Afzal M.; Gupta G.; Bhat A.A.; almalki W.H.; Kazmi I.; Alzarea S.I.; Pant K.; Ali H.; Paudel K.R.; Dureja H.; Singh T.G.; Singh S.K.; Dua K.; ncRNAs and their impact on dopaminergic neurons: Autophagy pathways in Parkinson\u2019s disease. Ageing Res Rev  2024,98,102327","journal-title":"Ageing Res Rev"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1007\/PL00000671","volume":"57","author":"L&#xFC;cking C.B.","year":"2000","unstructured":"L&#xFC;cking C.B.; Brice A.; Alpha-synuclein and Parkinson\u2019s disease. Cell Mol Life Sci  2000,57(13),1894-1908","journal-title":"Cell Mol Life Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00401-014-1255-5","volume":"127","author":"Nuber S.","year":"2014","unstructured":"Nuber S.; Tadros D.; Fields J.; Overk C.R.; Ettle B.; Kosberg K.; Mante M.; Rockenstein E.; Trejo M.; Masliah E.; Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD. Acta Neuropathol  2014,127(4),477-494","journal-title":"Acta Neuropathol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.3390\/cells10113022","volume":"10","author":"Vizziello M.","year":"2021","unstructured":"Vizziello M.; Borellini L.; Franco G.; Ardolino G.; Disruption of mitochondrial homeostasis: The role of PINK1 in Parkinson\u2019s disease. Cells  2021,10(11),3022","journal-title":"Cells"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1111\/ejn.14699","volume":"53","author":"Feng S.T.","year":"2021","unstructured":"Feng S.T.; Wang Z.Z.; Yuan Y.H.; Sun H.M.; Chen N.H.; Zhang Y.; Update on the association between alpha-synuclein and tau with mitochondrial dysfunction: Implications for Parkinson\u2019s disease. Eur J Neurosci  2021,53(9),2946-2959","journal-title":"Eur J Neurosci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40035-022-00281-6","volume":"11","author":"Pang S.Y.Y.","year":"2022","unstructured":"Pang S.Y.Y.; Lo R.C.N.; Ho P.W.L.; Liu H.F.; Chang E.E.S.; Leung C.T.; Malki Y.; Choi Z.Y.K.; Wong W.Y.; Kung M.H.W.; Ramsden D.B.; Ho S.L.; LRRK2, GBA and their interaction in the regulation of autophagy: Implications on therapeutics in Parkinson\u2019s disease. Transl Neurodegener  2022,11(1),5","journal-title":"Transl Neurodegener"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12974-023-02776-z","volume":"20","author":"Lind-Holm Mogensen F.","year":"2023","unstructured":"Lind-Holm Mogensen F.; Scafidi A.; Poli A.; Michelucci A.; PARK7\/DJ-1 in microglia: Implications in Parkinson\u2019s disease and relevance as a therapeutic target. J Neuroinflammation  2023,20(1),95","journal-title":"J Neuroinflammation"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1096\/fj.04-2751com","volume":"19","author":"Zhang W.","year":"2005","unstructured":"Zhang W.; Wang T.; Pei Z.; Miller D.S.; Wu X.; Block M.L.; Wilson B.; Zhang W.; Zhou Y.; Hong J.S.; Zhang J.; Aggregated &#x3B1;-synuclein activates microglia: A process leading to disease progression in Parkinson\u2019s disease. FASEB J  2005,19(6),533-542","journal-title":"FASEB J"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-017-1027-y","volume":"15","author":"Duffy M.F.","year":"2018","unstructured":"Duffy M.F.; Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. J Neuroinflammation  2018,15,1-18","journal-title":"J Neuroinflammation"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-019-01977-2","volume":"138","author":"Sorrentino Z.A.","year":"2019","unstructured":"Sorrentino Z.A.; Giasson B.I.; Chakrabarty P.; &#x3B1;-Synuclein and astrocytes: Tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. Acta Neuropathol  2019,138(1),1-21","journal-title":"Acta Neuropathol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/1531-8249(200004)47:4<521::AID-ANA18>3.0.CO;2-B","volume":"47","author":"Wakabayashi K.","year":"2000","unstructured":"Wakabayashi K.; Engelender S.; Yoshimoto M.; Tsuji S.; Ross C.A.; Takahashi H.; Synphilin-1 is present in Lewy bodies in Parkinson\u2019s disease. Ann Neurol  2000,47(4),521-523","journal-title":"Ann Neurol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"134316","DOI":"10.1016\/j.neulet.2019.134316","volume":"709","author":"Henderson M.X.","year":"2019","unstructured":"Henderson M.X.; Trojanowski J.Q.; Lee V.M.Y.; &#x3B1;-Synuclein pathology in Parkinson\u2019s disease and related &#x3B1;-synucleinopathies. Neurosci Lett  2019,709,134316","journal-title":"Neurosci Lett"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1124907","DOI":"10.3389\/fcell.2023.1124907","volume":"11","author":"Davidson K.","year":"2023","unstructured":"Davidson K.; Pickering A.M.; The proteasome: A key modulator of nervous system function, brain aging, and neurodegenerative disease. Front Cell Dev Biol  2023,11,1124907","journal-title":"Front Cell Dev Biol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"Dexter D.T.","year":"2013","unstructured":"Dexter D.T.; Jenner P.; Parkinson disease: From pathology to molecular disease mechanisms. Free Radic Biol Med  2013,62,132-144","journal-title":"Free Radic Biol Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3390\/biomedicines9111651","volume":"9","author":"Lei Y.","year":"2021","unstructured":"Lei Y.; Klionsky D.J.; The emerging roles of autophagy in human diseases. Biomedicines  2021,9(11),1651","journal-title":"Biomedicines"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s11010-020-04006-z","volume":"476","author":"Liao Z.","year":"2021","unstructured":"Liao Z.; Wang B.; Liu W.; Xu Q.; Hou L.; Song J.; Guo Q.; Li N.; Dysfunction of chaperone-mediated autophagy in human diseases. Mol Cell Biochem  2021,476(3),1439-1454","journal-title":"Mol Cell Biochem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/sj.cdd.4401438","volume":"11","author":"Sawada M.","year":"2004","unstructured":"Sawada M.; Kiyono T.; Nakashima S.; Shinoda J.; Naganawa T.; Hara S.; Iwama T.; Sakai N.; Molecular mechanisms of TNF-&#x3B1;-induced ceramide formation in human glioma cells:P53-mediated oxidant stress-dependent and -independent pathways. Cell Death Differ  2004,11(9),997-1008","journal-title":"Cell Death Differ"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"e1890","DOI":"10.1038\/cddis.2015.232","volume":"6","author":"Pastore D.","year":"2015","unstructured":"Pastore D.; Della-Morte D.; Coppola A.; Capuani B.; Lombardo M.F.; Pacifici F.; Ferrelli F.; Arriga R.; Mammi C.; Federici M.; Bellia A.; Di Daniele N.; Tesauro M.; Donadel G.; Noto D.; Sbraccia P.; Sconocchia G.; Lauro D.; SGK-1 protects kidney cells against apoptosis induced by ceramide and TNF-&#x3B1;. Cell Death Dis  2015,6(9),e1890-e1890","journal-title":"Cell Death Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2015.12.008","volume":"23","author":"Bellou V.","year":"2016","unstructured":"Bellou V.; Belbasis L.; Tzoulaki I.; Evangelou E.; Ioannidis J.P.A.; Environmental risk factors and Parkinson\u2019s disease: An umbrella review of meta-analyses. Parkinsonism Relat Disord  2016,23,1-9","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/acn3.758","volume":"6","author":"Ong Y.L.","year":"2019","unstructured":"Ong Y.L.; Deng X.; Tan E.K.; Etiologic links between environmental and lifestyle factors and Essential tremor. Ann Clin Transl Neurol  2019,6(5),979-989","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=56","first-page":"173","volume":"10","author":"Portero McLellan K.C.","year":"2014","unstructured":"Portero McLellan K.C.; Wyne K.; Villagomez E.T.; Hsueh W.A.; Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag  2014,10,173-188","journal-title":"Ther Clin Risk Manag"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"k2693","DOI":"10.1136\/bmj.k2693","volume":"362","author":"Douros A.","year":"2018","unstructured":"Douros A.; Dell\u2019Aniello S.; Yu O.H.Y.; Filion K.B.; Azoulay L.; Suissa S.; Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: Population based cohort study. BMJ  2018,362,k2693","journal-title":"BMJ"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/pon.3201","volume":"22","author":"Fu M.R.","year":"2013","unstructured":"Fu M.R.; Ridner S.H.; Hu S.H.; Stewart B.R.; Cormier J.N.; Armer J.M.; Psychosocial impact of lymphedema: A systematic review of literature from 2004 to 2011. Psychooncology  2013,22(7),1466-1484","journal-title":"Psychooncology"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fncel.2015.00124","volume":"9","author":"Chin-Chan M.","year":"2015","unstructured":"Chin-Chan M.; Navarro-Yepes J.; Quintanilla-Vega B.; Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci  2015,9,124","journal-title":"Front Cell Neurosci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/electronics12040783","volume":"12","author":"Dixit S.","year":"2023","unstructured":"Dixit S.; Bohre K.; Singh Y.; Himeur Y.; Mansoor W.; Atalla S.; Srinivasan K.; A Comprehensive review on AI-enabled models for Parkinson\u2019s disease diagnosis. Electronics (Basel)  2023,12(4),783","journal-title":"Electronics (Basel)"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"672838","DOI":"10.1155\/2015\/672838","volume":"2015","author":"Agim Z.S.","year":"2015","unstructured":"Agim Z.S.; Cannon J.R.; Dietary factors in the etiology of Parkinson\u2019s disease. Biomed Res Int  2015,2015,672838","journal-title":"Biomed Res Int"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1467-789X.2011.00893.x","volume":"12","author":"Joseph R.J.","year":"2011","unstructured":"Joseph R.J.; Alonso-Alonso M.; Bond D.S.; Pascual-Leone A.; Blackburn G.L.; The neurocognitive connection between physical activity and eating behaviour. Obes Rev  2011,12(10),800-812","journal-title":"Obes Rev"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3390\/antiox11071217","volume":"11","author":"Rudrapal M.","year":"2022","unstructured":"Rudrapal M.; Maji S.; Prajapati S.K.; Kesharwani P.; Deb P.K.; Khan J.; Mohamed Ismail R.; Kankate R.S.; Sahoo R.K.; Khairnar S.J.; Bendale A.R.; Protective effects of diets rich in polyphenols in cigarette smoke (CS)-induced oxidative damages and associated health implications. Antioxidants  2022,11(7),1217","journal-title":"Antioxidants"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"Jankovic J.","year":"2020","unstructured":"Jankovic J.; Tan E.K.; Parkinson\u2019s disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry  2020,91(8),795-808","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00702-015-1503-4","volume":"123","author":"Sampat R.","year":"2016","unstructured":"Sampat R.; Young S.; Rosen A.; Bernhard D.; Millington D.; Factor S.; Jinnah H.A.; Potential mechanisms for low uric acid in Parkinson disease. J Neural Transm (Vienna)  2016,123(4),365-370","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s00774-023-01446-7","volume":"41","author":"Ma C.","year":"2023","unstructured":"Ma C.; Yu R.; Li J.; Wang X.; Guo J.; Xiao E.; Liu P.; Association of serum uric acid levels with bone mineral density and the presence of osteoporosis in Chinese patients with Parkinson\u2019s disease: A cross-sectional study. J Bone Miner Metab  2023,41(5),714-726","journal-title":"J Bone Miner Metab"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/03639045.2022.2090575","volume":"48","author":"Yadav R.K.","year":"2022","unstructured":"Yadav R.K.; Shah K.; Dewangan H.K.; Intranasal drug delivery of sumatriptan succinate-loaded polymeric solid lipid nanoparticles for brain targeting. Drug Dev Ind Pharm  2022,48(1),21-28","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"167714","DOI":"10.1016\/j.jmb.2022.167714","volume":"435","author":"Gao V.","year":"2023","unstructured":"Gao V.; Briano J.A.; Komer L.E.; Burr&#xE9; J.; Functional and pathological effects of &#x3B1;-synuclein on synaptic SNARE complexes. J Mol Biol  2023,435(1),167714","journal-title":"J Mol Biol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.bbadis.2011.10.002","volume":"1822","author":"Breydo L.","year":"2012","unstructured":"Breydo L.; Wu J.W.; Uversky V.N.; &#x3B1;-Synuclein misfolding and Parkinson\u2019s disease. Biochim Biophys Acta Mol Basis Dis  2012,1822(2),261-285","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.neuroscience.2019.06.005","volume":"412","author":"Thakur P.","year":"2019","unstructured":"Thakur P.; Chiu W.H.; Roeper J.; Goldberg J.A.; &#x3B1;-Synuclein 2.0 \u2014 Moving towards Cell Type Specific Pathophysiology. Neuroscience  2019,412,248-256","journal-title":"Neuroscience"},{"key":"ref=71","first-page":"mdc3.131","volume":"2015","author":"Magrinelli F.","year":"2015","unstructured":"Magrinelli F.; Balint B.; Bhatia K. P.; Challenges in Clinicogenetic Correlations: One Gene\u2013Many Phenotypes Unravelling the Basis of Phenotypic Heterogeneity in Monogenic Disorders. Mov Disord Clin Pract  2015,2015,mdc3.131","journal-title":"Mov Disord Clin Pract"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"12134","DOI":"10.3390\/ijms241512134","volume":"24","author":"Graves N.J.","year":"2023","unstructured":"Graves N.J.; Gambin Y.; Sierecki E.; &#x3B1;-Synuclein Strains and Their Relevance to Parkinson\u2019s Disease, Multiple System Atrophy, and Dementia with Lewy Bodies. Int J Mol Sci  2023,24(15),12134","journal-title":"Int J Mol Sci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s13311-021-01017-6","volume":"18","author":"Tavassoly O.","year":"2021","unstructured":"Tavassoly O.; del Cid Pellitero E.; Larroquette F.; Cai E.; Thomas R.A.; Soubannier V.; Luo W.; Durcan T.M.; Fon E.A.; Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates &#x3B1;-synuclein Pathology in a Mouse Model of &#x3B1;-Synuclein Propagation. Neurotherapeutics  2021,18(2),979-997","journal-title":"Neurotherapeutics"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.xphs.2018.07.013","volume":"108","author":"Deepika D.","year":"2019","unstructured":"Deepika D.; Dewangan H.K.; Maurya L.; Singh S.; Intranasal Drug Delivery of Frovatriptan Succinate\u2013Loaded Polymeric Nanoparticles for Brain Targeting. J Pharm Sci  2019,108(2),851-859","journal-title":"J Pharm Sci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"100910","DOI":"10.1016\/j.jaging.2020.100910","volume":"56","author":"AboJabel H.","year":"2021","unstructured":"AboJabel H.; Argavan E.; Hassin-Baer S.; Inzelberg R.; Werner P.; Exploring the perceptions and stigmatizing experiences of Israeli family caregivers of people with Parkinson\u2019s disease. J Aging Stud  2021,56,100910","journal-title":"J Aging Stud"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"102658","DOI":"10.1016\/j.jelekin.2022.102658","volume":"64","author":"Romanato M.","year":"2022","unstructured":"Romanato M.; Piatkowska W.; Spolaor F.; To D.K.; Volpe D.; Sawacha Z.; Different perspectives in understanding muscle functions in Parkinson\u2019s disease through surface electromyography: Exploring multiple activation patterns. J Electromyogr Kinesiol  2022,64,102658","journal-title":"J Electromyogr Kinesiol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/mds.26510","volume":"31","author":"Marras C.","year":"2016","unstructured":"Marras C.; Chaudhuri K.R.; Nonmotor features of Parkinson\u2019s disease subtypes. Mov Disord  2016,31(8),1095-1102","journal-title":"Mov Disord"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1038\/s41380-022-01531-9","volume":"27","author":"Sirkis D.W.","year":"2022","unstructured":"Sirkis D.W.; Bonham L.W.; Johnson T.P.; La Joie R.; Yokoyama J.S.; Dissecting the clinical heterogeneity of early-onset Alzheimer\u2019s disease. Mol Psychiatry  2022,27(6),2674-2688","journal-title":"Mol Psychiatry"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.mito.2023.05.007","volume":"71","author":"Alqahtani T.","year":"2023","unstructured":"Alqahtani T.; Deore S.L.; Kide A.A.; Shende B.A.; Sharma R.; Dadarao Chakole R.; Nemade L.S.; Kishor Kale N.; Borah S.; Shrikant Deokar S.; Behera A.; Dhawal Bhandari D.; Gaikwad N.; Kalam Azad A.; Ghosh A.; Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease, and Parkinson\u2019s disease, Huntington\u2019s disease and Amyotrophic Lateral Sclerosis -An updated review. Mitochondrion  2023,71,83-92","journal-title":"Mitochondrion"},{"key":"ref=80","first-page":"1083","volume":"12","author":"Spano P.F.","year":"2013","unstructured":"Spano P.F.; Bellucci A.; Novel perspectives for Parkinson\u2019s disease therapy: insights from the latest advances in disease pathophysiology, diagnostic and experimental tools and molecular targets. CNS Neurol Disord Drug Targets  2013,12(8),1083-1085","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"101834","DOI":"10.1016\/j.arr.2022.101834","volume":"84","author":"Leite Silva A.B.R.","year":"2023","unstructured":"Leite Silva A.B.R.; Gon&#xE7;alves de Oliveira R.W.; Di&#xF3;genes G.P.; de Castro Aguiar M.F.; Sallem C.C.; Lima M.P.P.; de Albuquerque Filho L.B.; Peixoto de Medeiros S.D.; Penido de Mendon&#xE7;a L.L.; de Santiago Filho P.C.; Nones D.P.; da Silva Cardoso P.M.M.; Ribas M.Z.; Galv&#xE3;o S.L.; Gomes G.F.; Bezerra de Menezes A.R.; dos Santos N.L.; Moror&#xF3; V.M.; Duarte F.S.; dos Santos J.C.C.; Premotor, nonmotor and motor symptoms of Parkinson\u2019s Disease: A new clinical state of the art. Ageing Res Rev  2023,84,101834","journal-title":"Ageing Res Rev"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/mds.24996","volume":"27","author":"Postuma R.B.","year":"2012","unstructured":"Postuma R.B.; Aarsland D.; Barone P.; Burn D.J.; Hawkes C.H.; Oertel W.; Ziemssen T.; Identifying prodromal Parkinson\u2019s disease: Pre-Motor disorders in Parkinson\u2019s disease. Mov Disord  2012,27(5),617-626","journal-title":"Mov Disord"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s12264-017-0164-8","volume":"33","author":"Jin H.","year":"2017","unstructured":"Jin H.; Zhang J.R.; Shen Y.; Liu C.F.; Clinical Significance of REM Sleep Behavior Disorders and Other Non-motor Symptoms of Parkinsonism. Neurosci Bull  2017,33(5),576-584","journal-title":"Neurosci Bull"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"69393","DOI":"10.1007\/s11042-024-18186-z","volume":"83","author":"Keserwani P.K.","year":"2024","unstructured":"Keserwani P.K.; Das S.; Sarkar N.; A Comparative Study: Prediction of Parkinson\u2019s Disease Using Machine Learning, Deep Learning, and Nature Inspired Algorithm. Multimed Tools Appl  2024,83,69393-69441","journal-title":"Multimed Tools Appl"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/biom13091388","volume":"13","author":"Voicu V.","year":"2023","unstructured":"Voicu V.; Brehar F.M.; Toader C.; Covache-Busuioc R.A.; Corlatescu A.D.; Bordeianu A.; Costin H.P.; Bratu B.G.; Glavan L.A.; Ciurea A.V.; Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy. Biomolecules  2023,13(9),1388","journal-title":"Biomolecules"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"101328","DOI":"10.1016\/j.nantod.2021.101328","volume":"41","author":"Wu J.","year":"2021","unstructured":"Wu J.; Cui X.; Ke P.C.; Mortimer M.; Wang X.; Bao L.; Chen C.; Nanomaterials as novel agents for amelioration of Parkinson\u2019s disease. Nano Today  2021,41,101328","journal-title":"Nano Today"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"694","DOI":"10.14573\/altex.2203161","volume":"39","author":"Cassotta M.","year":"2022","unstructured":"Cassotta M.; Geerts H.; Harbom L.; Outeiro T.F.; Pediaditakis I.; Reiner O.; Schildknecht S.; Schwamborn J.C.; Bailey J.; Herrmann K.; Hogberg H.T.; The future of Parkinson\u2019s disease research: A new paradigm of human-specific investigation is necessary\u2026 and possible. Altern Anim Exp  2022,39(4),694-709","journal-title":"Altern Anim Exp"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"e0279616","DOI":"10.1371\/journal.pone.0279616","volume":"18","author":"Debnath S.","year":"2023","unstructured":"Debnath S.; Sharma D.; Chaudhari S.Y.; Sharma R.; Shaikh A.A.; Buchade R.S.; Kesari K.K.; Abdel-Fattah A.F.M.; Algahtani M.; Mheidat M.; Alsaidalani R.; Paul T.; Sayed A.A.; Abdel-Daim M.M.; Wheat ergot fungus-derived and modified drug for inhibition of intracranial aneurysm rupture due to dysfunction of TLR-4 receptor in Alzheimer\u2019s disease. PLoS One  2023,18(1),e0279616","journal-title":"PLoS One"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","volume":"12","author":"Fields C.R.","year":"2019","unstructured":"Fields C.R.; Bengoa-Vergniory N.; Wade-Martins R.; Targeting Alpha-Synuclein as a Therapy for Parkinson\u2019s Disease. Front Mol Neurosci  2019,12,299","journal-title":"Front Mol Neurosci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.27414","volume":"33","author":"Sardi S.P.","year":"2018","unstructured":"Sardi S.P.; Cedarbaum J.M.; Brundin P.; Targeted Therapies for Parkinson\u2019s Disease: From Genetics to the Clinic. Mov Disord  2018,33(5),684-696","journal-title":"Mov Disord"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s40263-020-00769-7","volume":"34","author":"Urso D.","year":"2020","unstructured":"Urso D.; Chaudhuri K.R.; Qamar M.A.; Jenner P.; Improving the Delivery of Levodopa in Parkinson\u2019s Disease: A Review of Approved and Emerging Therapies. CNS Drugs  2020,34(11),1149-1163","journal-title":"CNS Drugs"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/mds.26078","volume":"30","author":"Poewe W.","year":"2015","unstructured":"Poewe W.; Antonini A.; Novel formulations and modes of delivery of levodopa. Mov Disord  2015,30(1),114-120","journal-title":"Mov Disord"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/02652048.2023.2264386","volume":"40","author":"Neha S.L.","year":"2023","unstructured":"Neha S.L.; Mishra A.K.; Rani L.; Paroha S.; Dewangan H.K.; Sahoo P.K.; Design and evaluations of a nanostructured lipid carrier loaded with dopamine hydrochloride for intranasal bypass drug delivery in Parkinson\u2019s disease. J Microencapsul  2023,40(8),599-612","journal-title":"J Microencapsul"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/toxins7051629","volume":"7","author":"Strobl W.","year":"2015","unstructured":"Strobl W.; Theologis T.; Brunner R.; Kocer S.; Viehweger E.; Pascual-Pascual I.; Placzek R.; Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins (Basel)  2015,7(5),1629-1648","journal-title":"Toxins (Basel)"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.bjps.2017.01.009","volume":"70","author":"Cooper L.","year":"2017","unstructured":"Cooper L.; Lui M.; Nduka C.; Botulinum toxin treatment for facial palsy: A systematic review. J Plast Reconstr Aesthet Surg  2017,70(6),833-841","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2147\/NDT.S113099","volume":"13","author":"Dayabandara M.","year":"2017","unstructured":"Dayabandara M.; Hanwella R.; Ratnatunga S.; Seneviratne S.; Suraweera C.; de Silva V.; Antipsychotic-associated weight gain: Management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat  2017,13,2231-2241","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"863921","DOI":"10.3389\/fsurg.2022.863921","volume":"9","author":"Serva S.N.","year":"2022","unstructured":"Serva S.N.; Bernstein J.; Thompson J.A.; Kern D.S.; Ojemann S.G.; An update on advanced therapies for Parkinson\u2019s disease: From gene therapy to neuromodulation. Front Surg  2022,9,863921","journal-title":"Front Surg"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3727\/096368915X689622","volume":"25","author":"Squillaro T.","year":"2016","unstructured":"Squillaro T.; Peluso G.; Galderisi U.; Clinical Trials with Mesenchymal Stem Cells: An Update. Cell Transplant  2016,25(5),829-848","journal-title":"Cell Transplant"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.3233\/JPD-181489","volume":"8","author":"Ellis T.","year":"2018","unstructured":"Ellis T.; Rochester L.; Mobilizing Parkinson\u2019s Disease: The Future of Exercise. J Parkinsons Dis  2018,8(s1),S95-S100","journal-title":"J Parkinsons Dis"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2174\/1570159X20666220327212414","volume":"21","author":"Unnisa A.","year":"2023","unstructured":"Unnisa A.; Dua K.; Kamal M.A.; Mechanism of Mesenchymal Stem Cells as a Multitarget Disease- Modifying Therapy for Parkinson\u2019s Disease. Curr Neuropharmacol  2023,21(4),988-1000","journal-title":"Curr Neuropharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"19272","DOI":"10.1038\/s41598-023-44142-2","volume":"13","author":"Asano H.","year":"2023","unstructured":"Asano H.; Tian Y.S.; Hatabu A.; Takagi T.; Ueda M.; Ikeda K.; Suzuki Y.; Iida T.; Nishio A.; Safety comparisons among monoamine oxidase inhibitors against Parkinson\u2019s disease using FDA adverse event reporting system. Sci Rep  2023,13(1),19272","journal-title":"Sci Rep"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12883-023-03411-3","volume":"23","author":"Yang Y.","year":"2023","unstructured":"Yang Y.; Gao F.; Gao L.; Miao J.; Wang Q.; Zhao X.; Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson\u2019s disease. BMC Neurol  2023,23(1),360","journal-title":"BMC Neurol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/biomedicines10020371","volume":"10","author":"Gouda N.A.","year":"2022","unstructured":"Gouda N.A.; Elkamhawy A.; Cho J.; Emerging Therapeutic Strategies for Parkinson\u2019s Disease and Future Prospects: A 2021 Update. Biomedicines  2022,10(2),371","journal-title":"Biomedicines"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41531-024-00747-6","volume":"10","author":"Nielsen J.","year":"2024","unstructured":"Nielsen J.; Lauritsen J.; Pedersen J.N.; Nowak J.S.; Bendtsen M.K.; Kleijwegt G.; Lusser K.; Pitarch L.C.; Moreno J.V.; Schneider M.M.; Krainer G.; Goks&#xF8;yr L.; Khalif&#xE9; P.; Kaalund S.S.; Aznar S.; Kj&#xE6;rgaard M.; Sereikait&#xE9; V.; Str&#xF8;mgaard K.; Knowles T.P.J.; Nielsen M.A.; Sander A.F.; Romero-Ramos M.; Otzen D.E.; Molecular properties and diagnostic potential of monoclonal antibodies targeting cytotoxic &#x3B1;-synuclein oligomers. NPJ Parkinsons Dis  2024,10(1),139","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pneurobio.2018.09.003","volume":"177","author":"Gr&#xFC;newald A.","year":"2019","unstructured":"Gr&#xFC;newald A.; Kumar K.R.; Sue C.M.; New insights into the complex role of mitochondria in Parkinson\u2019s disease. Prog Neurobiol  2019,177,73-93","journal-title":"Prog Neurobiol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/jnc.13583","volume":"139","author":"Golde T.E.","year":"2016","unstructured":"Golde T.E.; Overcoming translational barriers impeding development of Alzheimer\u2019s disease modifying therapies. J Neurochem  2016,139(S2)(Suppl. 2),224-236","journal-title":"J Neurochem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"iv43","DOI":"10.1007\/s00415-005-4009-4","volume":"252","author":"Stocchi F.","year":"2005","unstructured":"Stocchi F.; Optimising levodopa therapy for the management of Parkinson\u2019s disease. J Neurol  2005,252(S4)(Suppl. 4),iv43-iv48","journal-title":"J Neurol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14737175.2023.2176220","volume":"23","author":"Lees A.","year":"2023","unstructured":"Lees A.; Tolosa E.; Stocchi F.; Ferreira J.J.; Rascol O.; Antonini A.; Poewe W.; Schapira A.; Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Rev Neurother  2023,23(1),15-24","journal-title":"Expert Rev Neurother"},{"key":"ref=109","first-page":"146","volume":"5","author":"Okereke C.S.","year":"2002","unstructured":"Okereke C.S.; Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson\"s disease patients experiencing motor fluctuations with levodopa. J Pharm Pharm Sci  2002,5(2),146-161","journal-title":"J Pharm Pharm Sci"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1093\/advances\/nmab060","volume":"12","author":"Boelens Keun J.T.","year":"2021","unstructured":"Boelens Keun J.T.; Arnoldussen I.A.; Vriend C.; van de Rest O.; Ibrahim N.; Dietary approaches to improve efficacy and control side effects of levodopa therapy in parkinson\u2019s disease: A systematic review. Adv Nutr  2021,12(6),2265-2287","journal-title":"Adv Nutr"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/NDT.S273121","volume":"19","author":"Masood N.","year":"2023","unstructured":"Masood N.; Jimenez-Shahed J.; Effective Management of &#x201C;OFF&#x201D; Episodes in Parkinson\u2019s Disease: Emerging Treatment Strategies and Unmet Clinical Needs. Neuropsychiatr Dis Treat  2023,19,247-266","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/pharmaceutics15051503","volume":"15","author":"Nakmode D.D.","year":"2023","unstructured":"Nakmode D.D.; Day C.M.; Song Y.; Garg S.; Zheng X.; Li D.; Yang W.; The management of parkinson\u2019s disease: An overview of the current advancements in drug delivery systems. Pharmaceutics  2023,15(5),1503","journal-title":"Pharmaceutics"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1002\/mdc3.13786","volume":"10","author":"Antonini A.","year":"2023","unstructured":"Antonini A.; Emmi A.; Campagnolo M.; Beyond the dopaminergic system: Lessons learned from levodopa resistant symptoms in parkinson\u2019s disease. Mov Disord Clin Pract (Hoboken)  2023,10(S2)(Suppl. 2),S50-S55","journal-title":"Mov Disord Clin Pract (Hoboken)"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3109\/00207459608986356","volume":"85","author":"Sandyk R.","year":"1996","unstructured":"Sandyk R.; Freezing of gait in Parkinson\u2019s disease is improved by treatment with weak electromagnetic fields. Int J Neurosci  1996,85(1-2),111-124","journal-title":"Int J Neurosci"},{"key":"ref=115","author":"Bhidayasiri R.","year":"2024","unstructured":"Bhidayasiri R.; Prasertpan T.; Tinazzi M.;  Handbook of digital technologies in movement disorders  2024","journal-title":"Handbook of digital technologies in movement disorders"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9131474","volume":"2020","author":"Pirto\u0161ek Z.","year":"2020","unstructured":"Pirto\u0161ek Z.; Bajenaru O.; Kov&#xE1;cs N.; Milanov I.; Relja M.; Skorvanek M.; Update on the management of parkinson\u2019s disease for general neurologists. Parkinsons Dis  2020,2020,1-13","journal-title":"Parkinsons Dis"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/WCO.0000000000000118","volume":"27","author":"Giugni J.C.","year":"2014","unstructured":"Giugni J.C.; Okun M.S.; Treatment of advanced Parkinson\u2019s disease. Curr Opin Neurol  2014,27(4),450-460","journal-title":"Curr Opin Neurol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s40263-013-0053-2","volume":"27","author":"Sprenger F.","year":"2013","unstructured":"Sprenger F.; Poewe W.; Management of motor and non-motor symptoms in Parkinson\u2019s disease. CNS Drugs  2013,27(4),259-272","journal-title":"CNS Drugs"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"110539","DOI":"10.1016\/j.cellsig.2022.110539","volume":"102","author":"Punyakoti P.","year":"2023","unstructured":"Punyakoti P.; Behl T.; Sehgal A.; Yadav S.; Sachdeva M.; Anwer M.K.; Vargas-De-La-Cruz C.; Venkatachalam T.; Naqvi M.; Verma R.; Tuli H.S.; Postulating the possible cellular signalling mechanisms of antibody drug conjugates in Alzheimer\u2019s disease. Cell Signal  2023,102,110539","journal-title":"Cell Signal"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00702-019-02113-w","volume":"127","author":"Pup&#xED;kov&#xE1; M.","year":"2020","unstructured":"Pup&#xED;kov&#xE1; M.; Rektorov&#xE1; I.; Non-pharmacological management of cognitive impairment in Parkinson\u2019s disease. J Neural Transm (Vienna)  2020,127(5),799-820","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1177\/0269881118805496","volume":"32","author":"Santos B.","year":"2018","unstructured":"Santos B.; Gonz&#xE1;lez-Fraile E.; Zabala A.; Guill&#xE9;n V.; Rueda J.R.; Ballesteros J.; Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia. J Psychopharmacol  2018,32(11),1155-1166","journal-title":"J Psychopharmacol"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21467\/ijm.1.1.2016.29","volume":"1","author":"Tomar S.","year":"2022","unstructured":"Tomar S.; Yadav R.K.; Shah K.; Dewangan H.K.; A Comprehensive Review on Carrier Mediated Nose to Brain Targeting: Emphasis on Molecular Targets, Current Trends, Future Prospects, and Challenges. Int J Polym Mater  2022,1,1-23","journal-title":"Int J Polym Mater"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1251395","DOI":"10.3389\/fneur.2023.1251395","volume":"14","author":"van den Bergh R.","year":"2023","unstructured":"van den Bergh R.; Evers L.J.W.; de Vries N.M.; Silva de Lima A.L.; Bloem B.R.; Valenti G.; Meinders M.J.; Usability and utility of a remote monitoring system to support physiotherapy for people with Parkinson\u2019s disease. Front Neurol  2023,14,1251395","journal-title":"Front Neurol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fneur.2017.00042","volume":"8","author":"Loddo G.","year":"2017","unstructured":"Loddo G.; Calandra-Buonaura G.; Sambati L.; Giannini G.; Cecere A.; Cortelli P.; Provini F.; The Treatment of Sleep Disorders in Parkinson\u2019s Disease: From Research to Clinical Practice. Front Neurol  2017,8,42","journal-title":"Front Neurol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"111435","DOI":"10.1016\/j.jpsychores.2023.111435","volume":"172","author":"Sun A.","year":"2023","unstructured":"Sun A.; Wu X.; Efficacy of non-pharmacological interventions on improving sleep quality in depressed patients: A systematic review and network meta-analysis. J Psychosom Res  2023,172,111435","journal-title":"J Psychosom Res"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11920-009-0004-2","volume":"11","author":"Deschenes C.L.","year":"2009","unstructured":"Deschenes C.L.; McCurry S.M.; Current treatments for sleep disturbances in individuals with dementia. Curr Psychiatry Rep  2009,11(1),20-26","journal-title":"Curr Psychiatry Rep"},{"key":"ref=127","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-53497-2.00009-7","author":"Pollak P.","year":"2013","unstructured":"Pollak P.;  Handbook of Clinical Neurology  2013","journal-title":"Handbook of Clinical Neurology"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00702-018-1906-0","volume":"125","author":"Antonini A.","year":"2018","unstructured":"Antonini A.; Nitu B.; Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. J Neural Transm (Vienna)  2018,125(8),1131-1135","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.parkreldis.2016.11.019","volume":"33","author":"van Laar T.","year":"2016","unstructured":"van Laar T.; Borgemeester R.; The need for non-oral therapy in Parkinson\u2019s disease; a potential role for apomorphine. Parkinsonism Relat Disord  2016,33(Suppl. 1),S22-S27","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/pgmj.2003.013912","volume":"80","author":"Thanvi B.R.","year":"2004","unstructured":"Thanvi B.R.; Lo T.C.N.; Long term motor complications of levodopa: Clinical features, mechanisms, and management strategies. Postgrad Med J  2004,80(946),452-458","journal-title":"Postgrad Med J"},{"key":"ref=131","first-page":"287","volume":"7","author":"Sura L.","year":"2012","unstructured":"Sura L.; Madhavan A.; Carnaby G.; Crary M.A.; Dysphagia in the elderly: Management and nutritional considerations. Clin Interv Aging  2012,7,287-298","journal-title":"Clin Interv Aging"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.jamda.2021.02.039","volume":"22","author":"Malafarina V.","year":"2021","unstructured":"Malafarina V.; Serra Rexach J.A.; Masan&#xE9;s F.; Cervera-D&#xED;az M.C.; Lample Lacasa L.; Ollero Ortigas A.; Cruz-Jentoft A.J.; Results of High-Protein, High-Calorie Oral Nutritional Supplementation in Malnourished Older People in Nursing Homes: An Observational, Multicenter, Prospective, Pragmatic Study (PROT-e-GER). J Am Med Dir Assoc  2021,22(9),1919-1926.e5","journal-title":"J Am Med Dir Assoc"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1044\/2023_AJSLP-22-00278","volume":"32","author":"Koster E.","year":"2023","unstructured":"Koster E.; Wadhwaniya Z.; Namasivayam-MacDonald A.M.; Preliminary Study of the Effects of a Dysphagia Support Group on Quality of Life. Am J Speech Lang Pathol  2023,32(4),1466-1488","journal-title":"Am J Speech Lang Pathol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.3390\/nu15204371","volume":"15","author":"Nagano A.","year":"2023","unstructured":"Nagano A.; Onaka M.; Maeda K.; Ueshima J.; Shimizu A.; Ishida Y.; Nagami S.; Miyahara S.; Nishihara K.; Yasuda A.; Satake S.; Mori N.; Prevalence and Characteristics of the Course of Dysphagia in Hospitalized Older Adults. Nutrients  2023,15(20),4371","journal-title":"Nutrients"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/nu16020246","volume":"16","author":"Utrilla Fornals A.","year":"2024","unstructured":"Utrilla Fornals A.; Costas-Batlle C.; Medlin S.; Menj&#xF3;n-Lajusticia E.; Cisneros-Gonz&#xE1;lez J.; Saura-Carmona P.; Montoro-Huguet M.A.; Metabolic and Nutritional Issues after Lower Digestive Tract Surgery: The Important Role of the Dietitian in a Multidisciplinary Setting. Nutrients  2024,16(2),246","journal-title":"Nutrients"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"597451","DOI":"10.3389\/fneur.2020.597451","volume":"11","author":"Sui Y.","year":"2021","unstructured":"Sui Y.; Tian Y.; Ko W.K.D.; Wang Z.; Jia F.; Horn A.; De Ridder D.; Choi K.S.; Bari A.A.; Wang S.; Hamani C.; Baker K.B.; Machado A.G.; Aziz T.Z.; Fonoff E.T.; K&#xFC;hn A.A.; Bergman H.; Sanger T.; Liu H.; Haber S.N.; Li L.; Deep Brain Stimulation Initiative: Toward Innovative Technology, New Disease Indications, and Approaches to Current and Future Clinical Challenges in Neuromodulation Therapy. Front Neurol  2021,11,597451","journal-title":"Front Neurol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1044\/2020_JSLHR-20-00256","volume":"64","author":"Sandstr&#xF6;m L.","year":"2021","unstructured":"Sandstr&#xF6;m L.; Schalling E.; Karlsson F.; Blomstedt P.; Hartelius L.; Speech Function Following Deep Brain Stimulation of the Caudal Zona Incerta: Effects of Habitual and High-Amplitude Stimulation. J Speech Lang Hear Res  2021,64(6S),2121-2133","journal-title":"J Speech Lang Hear Res"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1007\/s00415-023-11873-1","volume":"270","author":"Oliveira A.M.","year":"2023","unstructured":"Oliveira A.M.; Coelho L.; Carvalho E.; Ferreira-Pinto M.J.; Vaz R.; Aguiar P.; Machine learning for adaptive deep brain stimulation in Parkinson\u2019s disease: Closing the loop. J Neurol  2023,270(11),5313-5326","journal-title":"J Neurol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-024-03196-z","volume":"1","author":"Oehrn C.R.","year":"2024","unstructured":"Oehrn C.R.; Cernera S.; Hammer L.H.; Shcherbakova M.; Yao J.; Hahn A.; Wang S.; Ostrem J.L.; Little S.; Starr P.A.; Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson\u2019s disease: A blinded randomized feasibility trial. Nat Med  2024,1,1-12","journal-title":"Nat Med"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"e3474","DOI":"10.7759\/cureus.3474","volume":"10","author":"Bratsos S.P.","year":"2018","unstructured":"Bratsos S.P.; Karponis D.; Saleh S.N.; Efficacy and Safety of Deep Brain Stimulation in the Treatment of Parkinson\u2019s Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Cureus  2018,10(10),e3474","journal-title":"Cureus"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/mds.23714","volume":"26","author":"Rascol O.","year":"2011","unstructured":"Rascol O.; Lozano A.; Stern M.; Poewe W.; Milestones in Parkinson\u2019s disease therapeutics. Mov Disord  2011,26(6),1072-1082","journal-title":"Mov Disord"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/jamaneurol.2017.4321","volume":"75","author":"Ramirez-Zamora A.","year":"2018","unstructured":"Ramirez-Zamora A.; Ostrem J.L.; Globus Pallidus Interna or Subthalamic Nucleus Deep Brain Stimulation for Parkinson Disease. JAMA Neurol  2018,75(3),367-372","journal-title":"JAMA Neurol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"38ra46","DOI":"10.1126\/scitranslmed.3000976","volume":"2","author":"Politis M.","year":"2010","unstructured":"Politis M.; Wu K.; Loane C.; Quinn N.P.; Brooks D.J.; Rehncrona S.; Bjorklund A.; Lindvall O.; Piccini P.; Serotonergic neurons mediate dyskinesia side effects in Parkinson\u2019s patients with neural transplants. Sci Transl Med  2010,2(38),38ra46","journal-title":"Sci Transl Med"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.neuroscience.2021.03.022","volume":"463","author":"Guo X.","year":"2021","unstructured":"Guo X.; Tang L.; Tang X.; Current Developments in Cell Replacement Therapy for Parkinson\u2019s Disease. Neuroscience  2021,463,370-382","journal-title":"Neuroscience"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2018.04.005","volume":"168","author":"Sonntag K.C.","year":"2018","unstructured":"Sonntag K.C.; Song B.; Lee N.; Jung J.H.; Cha Y.; Leblanc P.; Neff C.; Kong S.W.; Carter B.S.; Schweitzer J.; Kim K.S.; Pluripotent stem cell-based therapy for Parkinson\u2019s disease: Current status and future prospects. Prog Neurobiol  2018,168,1-20","journal-title":"Prog Neurobiol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/mds.28628","volume":"36","author":"Barbuti P.A.","year":"2021","unstructured":"Barbuti P.A.; Barker R.A.; Brundin P.; Przedborski S.; Papa S.M.; Kalia L.V.; Mochizuki H.; Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson\u2019s Disease. Mov Disord  2021,36(8),1772-1780","journal-title":"Mov Disord"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/cells8010026","volume":"8","author":"Stoddard-Bennett T.","year":"2019","unstructured":"Stoddard-Bennett T.; Reijo Pera R.; Treatment of Parkinson\u2019s Disease through Personalized Medicine and Induced Pluripotent Stem Cells. Cells  2019,8(1),26","journal-title":"Cells"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/bs.pbr.2016.11.011","volume":"230","author":"Kirkeby A.","year":"2017","unstructured":"Kirkeby A.; Parmar M.; Barker R.A.; Strategies for bringing stem cell-derived dopamine neurons to the clinic. Prog Brain Res  2017,230,165-190","journal-title":"Prog Brain Res"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41591-019-0507-2","volume":"25","author":"Barker R.A.","year":"2019","unstructured":"Barker R.A.; Designing stem-cell-based dopamine cell replacement trials for Parkinson\u2019s disease. Nat Med  2019,25(7),1045-1053","journal-title":"Nat Med"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.stem.2023.08.014","volume":"30","author":"Kirkeby A.","year":"2023","unstructured":"Kirkeby A.; Nelander J.; Hoban D.B.; Rogelius N.; Bjartmarz H.; Storm P.; Fiorenzano A.; Adler A.F.; Vale S.; Mudannayake J.; Zhang Y.; Cardoso T.; Mattsson B.; Landau A.M.; Glud A.N.; S&#xF8;rensen J.C.; Lillethorup T.P.; Lowdell M.; Carvalho C.; Bain O.; van Vliet T.; Lindvall O.; Bj&#xF6;rklund A.; Harry B.; Cutting E.; Widner H.; Paul G.; Barker R.A.; Parmar M.; Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson\u2019s disease, STEM-PD. Cell Stem Cell  2023,30(10),1299-1314.e9","journal-title":"Cell Stem Cell"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5604\/01.3001.0016.2849","volume":"16","author":"Koz\u0142owska M.","year":"2023","unstructured":"Koz\u0142owska M.; Kotarba S.; Tambor J.; Winiarski M.; Moczulska H.; Pietrusi\u0144ski M.; Borowiec M.; Parkinson\u2019s disease gene therapy: A comparative effectiveness review of completed clinical trials in terms of their possible implementation in treatment. Med Sci Pulse  2023,16(4),1-7","journal-title":"Med Sci Pulse"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/ph16101416","volume":"16","author":"Shchaslyvyi A.Y.","year":"2023","unstructured":"Shchaslyvyi A.Y.; Antonenko S.V.; Tesliuk M.G.; Telegeev G.D.; Current State of Human Gene Therapy: Approved Products and Vectors. Pharmaceuticals (Basel)  2023,16(10),1416","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2174\/1570159X21666221121094343","volume":"22","author":"Hvingelby V.S.","year":"2024","unstructured":"Hvingelby V.S.; Pavese N.; Surgical Advances in Parkinson\u2019s Disease. Curr Neuropharmacol  2024,22(6),1033-1046","journal-title":"Curr Neuropharmacol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/mds.27033","volume":"32","author":"Yadav A.P.","year":"2017","unstructured":"Yadav A.P.; Nicolelis M.A.L.; Electrical stimulation of the dorsal columns of the spinal cord for Parkinson\u2019s disease. Mov Disord  2017,32(6),820-832","journal-title":"Mov Disord"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.neurom.2023.06.003","volume":"26","author":"Ciocca M.","year":"2023","unstructured":"Ciocca M.; Seemungal B.M.; Tai Y.F.; Spinal Cord Stimulation for Gait Disorders in Parkinson\u2019s Disease and Atypical Parkinsonism: A Systematic Review of Preclinical and Clinical Data. Neuromodulation  2023,26(7),1339-1361","journal-title":"Neuromodulation"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S1474-4422(18)30287-4","volume":"17","author":"James N.D.","year":"2018","unstructured":"James N.D.; McMahon S.B.; Field-Fote E.C.; Bradbury E.J.; Neuromodulation in the restoration of function after spinal cord injury. Lancet Neurol  2018,17(10),905-917","journal-title":"Lancet Neurol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/ner.12591","volume":"20","author":"Nagel S.J.","year":"2017","unstructured":"Nagel S.J.; Wilson S.; Johnson M.D.; Machado A.; Frizon L.; Chardon M.K.; Reddy C.G.; Gillies G.T.; Howard M.A.; Spinal Cord Stimulation for Spasticity: Historical Approaches, Current Status, and Future Directions. Neuromodulation  2017,20(4),307-321","journal-title":"Neuromodulation"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501319817240919103802","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/234624\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501319817240919103802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T19:53:44Z","timestamp":1735070024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/234624\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":157,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501319817240919103802","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}